Apricus Biosciences merges with Seelos Therapeutics
Custom Synthesis, Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday, and will focus on bringing to shelves central nervous system (CNS) therapeutics.
Upon completion of the proposed merger, the name of the merged company will be Seelos Therapeutics, Inc., and the company is about to be trading on the Nasdaq Capital Market under the ticker symbol “SEEL.” It will remain headquartered in New York.
As revealed in the press release, Raj Mehra, Chairman, founder & CEO of Seelos will serve as the Chairman, CEO and President of the merged company, and Richard Pascoe, CEO of Apricus will serve on the Board of Directors. Other board members will include: Robin L. Smith, M.D., Chairman of the Board of The Stem for Life Foundation; Daniel J. O’Connor, CEO of OncoSec Medical, Inc.; and Brian Lian, Ph.D., CEO and President of Viking Therapeutics, Inc.
We specialize in custom synthesis manufacturing pharmaceutical intermediates with the highest technology and stable quality control , our factory has sophisticated technology production route to produce this product ,welcome to inquiry it . Please contact us by e-mail email@example.com for quotation requests. Please provide quantity, purity, and any other specific requirements 。http://www.haihengpharma.com/apricus-biosciences-merges-with-seelos-therapeutics/News